iPS Cells

Følg
Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
Bilde generert av AI

Health ministry panel conditionally approves iPS cell products

Rapportert av AI Bilde generert av AI

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis